Filtered By:
Vaccination: Cancer Vaccines

This page shows you your search results in order of date. This is page number 18.

Order by Relevance | Date

Total 479 results found since Jan 2013.

Integration of prevention and control measures for female genital schistosomiasis, HIV and cervical cancer.
Abstract Female genital schistosomiasis as a result of chronic infection with Schistosoma haematobium (commonly known as bilharzia) continues to be largely ignored by national and global health policy-makers. International attention for large-scale action against the disease focuses on whether it is a risk factor for the transmission of human immunodeficiency virus (HIV). Yet female genital schistosomiasis itself is linked to pain, bleeding and sub- or infertility, leading to social stigma, and is a common issue for women in schistosomiasis-endemic areas in sub-Saharan Africa. The disease should therefore be recog...
Source: Bulletin of the World Health Organization - August 31, 2020 Category: International Medicine & Public Health Authors: Engels D, Hotez PJ, Ducker C, Gyapong M, Bustinduy AL, Secor WE, Harrison W, Theobald S, Thomson R, Gamba V, Masong MC, Lammie P, Govender K, Mbabazi PS, Malecela MN Tags: Bull World Health Organ Source Type: research

Fight Aging! Newsletter, August 24th 2020
We report that electrical stimulation (ES) stimulation of post-stroke aged rats led to an improved functional recovery of spatial long-term memory (T-maze), but not on the rotating pole or the inclined plane, both tests requiring complex sensorimotor skills. Surprisingly, ES had a detrimental effect on the asymmetric sensorimotor deficit. Histologically, there was a robust increase in the number of doublecortin-positive cells in the dentate gyrus and SVZ of the infarcted hemisphere and the presence of a considerable number of neurons expressing tubulin beta III in the infarcted area. Among the genes that were unique...
Source: Fight Aging! - August 23, 2020 Category: Research Authors: Reason Tags: Newsletters Source Type: blogs

4 Examples Of Merging Gaming & Digital Health
Pausing to check his map, Sam confirms that he is on the right track for his next delivery, only 2 kilometres left. He takes the opportunity to quench his thirst and check if his delivery load is securely attached to his back; some contain fragile vials of medicines and digital pills susceptible to damage if handled inappropriately. After making sure of the integrity of those packages, Sam takes a final look at his surroundings. “It’s quite peaceful with nobody around,” he thinks to himself and resumes his path.  Upon arrival at his destination, his gear is disinfected before he has access to the inte...
Source: The Medical Futurist - August 4, 2020 Category: Information Technology Authors: Prans Tags: Artificial Intelligence Augmented Reality Digital Health Research Healthcare Design Healthcare Policy Telemedicine & Smartphones Virtual Reality fda gamification Fitbit covid19 Apple Watch WHO gaming roche MySugr Foldit A Source Type: blogs

What's New in Vaccine Science.
Abstract Today vaccines can provide immunity against and treatment of a growing number of diseases including noninfectious conditions. Vaccine science continues to evolve newer and safer ways to deliver prevention and treatment of infectious and noninfectious diseases. This includes new adjuvants to enhance immunogenicity; delivery systems to reduce pain and improve acceptability; a wider range of uses including preventing emerging infectious diseases, such as Zika virus and Ebola, treatment of chronic diseases, such as cancer, and autoimmune disorders; and repurposing of existing vaccines, such as bacillus Calmet...
Source: Primary Care - July 29, 2020 Category: Primary Care Authors: Savoy M Tags: Prim Care Source Type: research

Moderna Begins Testing Coronavirus Vaccine On 30,000 Volunteers
CAMBRIDGE (AP) – The world’s biggest COVID-19 vaccine study got underway Monday with the first of 30,000 planned volunteers helping to test shots created by the U.S. government — one of several candidates in the final stretch of the global vaccine race. There’s still no guarantee that the experimental vaccine, developed by the National Institutes of Health and Moderna Inc., will really protect. The needed proof: Volunteers won’t know if they’re getting the real shot or a dummy version. After two doses, scientists will closely track which group experiences more infections as they go about...
Source: WBZ-TV - Breaking News, Weather and Sports for Boston, Worcester and New Hampshire - July 27, 2020 Category: Consumer Health News Authors: Health – CBS Boston Tags: Boston News Business Covid-19 Boston, MA Featured Health Healthcare Status Syndicated CBSN Boston Coronavirus Coronavirus Vaccine Moderna Moderna Therapeutics Source Type: news

What ’s New in Vaccine Science
Today vaccines can provide immunity against and treatment of a growing number of diseases including noninfectious conditions. Vaccine science continues to evolve newer and safer ways to deliver prevention and treatment of infectious and noninfectious diseases. This includes new adjuvants to enhance immunogenicity; delivery systems to reduce pain and improve acceptability; a wider range of uses including preventing emerging infectious diseases, such as Zika virus and Ebola, treatment of chronic diseases, such as cancer, and autoimmune disorders; and repurposing of existing vaccines, such as bacillus Calmette-Gu érin for novel therapies.
Source: Primary Care: Clinics in Office Practice - July 3, 2020 Category: Primary Care Authors: Margot Savoy Source Type: research

Janssen Announces Discontinuation of Phase 3 LOTUS Study Evaluating Ustekinumab in Systemic Lupus Erythematosus
SPRING HOUSE, PENNSYLVANIA, June 26, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today its decision to discontinue the Phase 3 LOTUS study of STELARA® (ustekinumab) in Systemic Lupus Erythematosus (SLE) due to lack of efficacy in SLE.The decision is based on data from a pre-planned interim efficacy analysis. Interim safety findings were consistent with the known safety profile of STELARA, and no new safety signals were identified. Investigators, study participants and health authorities have been informed of the decision. The company intends to thoroughly analyze the totality of the st...
Source: Johnson and Johnson - June 26, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news

Subcutaneous Daratumumab Combination Resulted in Deep and Rapid Hematologic Responses and Improved Clinical Outcomes in the Treatment of Patients with Newly Diagnosed Light Chain (AL) Amyloidosis
RARITAN, NJ, June 13, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today results from the first randomized Phase 3 study investigating subcutaneous daratumumab[i] in the treatment of patients with newly diagnosed light chain (AL) amyloidosis, a rare and potentially fatal disease.[1],[2] The data demonstrated subcutaneous daratumumab in combination with cyclophosphamide, bortezomib, and dexamethasone (D-CyBorD) resulted in a higher hematologic complete response rate (CR), (53 percent vs. 18 percent [P<0.0001]), compared to CyBorD. Additionally, treatment with D-CyBorD delayed the time ...
Source: Johnson and Johnson - June 15, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news

NIDCR's Summer 2020 E-Newsletter
Having trouble viewing this email? View it as a Web page. NIDCR's Summer 2020 E-Newsletter In this issue: NIDCR News Funding Opportunities NIH/HHS News Funding Notices Science Advances Subscribe to NICDR News Grantee News   NIDCR News NIDCR Announces Availability of COVID-19 Research Funding On May 5, NIDCR issued two Notices of Special Interest highlighting the urgent need for research on coronavirus disease 2019. This research may be conducted either via the National Dental PBRN infrastructure or in...
Source: NIDCR Science News - June 4, 2020 Category: Dentistry Source Type: news

Can celiac disease affect life expectancy?
Celiac disease (CD), triggered by the ingestion of gluten, occurs in people genetically predisposed to develop the chronic autoimmune condition. During the past few decades, doctors have learned much about how the disease develops, including genetic and other risk factors. However, results from studies on whether people with CD have an increased risk of premature death linked to the condition have been mixed. A recent study shows a small but statistically significant increased mortality rate. Celiac disease can affect the entire body Until recently, CD was considered a mainly pediatric gastrointestinal disorder, associated...
Source: Harvard Health Blog - May 28, 2020 Category: Consumer Health News Authors: Maureen Leonard, MD, MMSc Tags: Allergies Autoimmune diseases Source Type: blogs

Fight Aging! Newsletter, May 25th 2020
In conclusion, our results suggest a previously unknown mechanism whereby the canonical NF-κB cascade and a mitochondrial fission pathway interdependently regulate endothelial inflammation. Lin28 as a Target for Nerve Regeneration https://www.fightaging.org/archives/2020/05/lin28-as-a-target-for-nerve-regeneration/ Researchers here show that the gene Lin28 regulates axon regrowth. In mice, raised levels of Lin28 produce greater regeneration of nerve injuries. Past research has investigated Lin28 from the standpoint of producing a more general improvement in regenerative capacity. It improves mitochondri...
Source: Fight Aging! - May 24, 2020 Category: Research Authors: Reason Tags: Newsletters Source Type: blogs

Some healthcare can safely wait (and some can ’t)
Among the many remarkable things that have happened since the COVID-19 pandemic began is that a lot of our usual medical care has simply stopped. According to a recent study, routine testing for cervical cancer, cholesterol, and blood sugar is down nearly 70% across the country. Elective surgeries, routine physical examinations, and other screening tests have been canceled or rescheduled so that people can stay at home, avoid being around others who might be sick, and avoid unknowingly spreading the virus. Many clinics, hospitals, and doctors’ offices have been closed for weeks except for emergencies. Even if these facil...
Source: Harvard Health Blog - May 20, 2020 Category: Consumer Health News Authors: Robert H. Shmerling, MD Tags: Health Health care Healthy Aging Men's Health Women's Health Source Type: blogs

Top 20 Research Studies of 2019 for Primary Care Physicians.
This article summarizes the clinical questions and bottom-line answers from the top 20 POEMs of 2019. Taking blood pressure medications at night results in a large mortality reduction over six years compared with morning dosing. Automated devices are the best way to measure blood pressure. Nonfasting lipid profiles are preferred over fasting lipid profiles, and nonfasting and fasting lipid profiles are equally effective at predicting risk. The benefit of statins for primary prevention in people 75 years and older is uncertain at best. Aspirin has no net benefit for primary prevention of cardiovascular disease and has no ef...
Source: American Family Physician - May 14, 2020 Category: Primary Care Authors: Ebell MH, Grad R Tags: Am Fam Physician Source Type: research

Janssen ’s BCMA CAR-T Therapy JNJ-4528 Showed Early, Deep and Durable Responses in Heavily Pretreated Patients with Multiple Myeloma
RARITAN, NJ, May 13, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today updated results from the Phase 1b/2 CARTITUDE-1 study (NCT03548207) evaluating the efficacy and safety of JNJ-4528, an investigational B-cell maturation antigen (BCMA)-directed chimeric antigen receptor T cell (CAR-T) therapy in the treatment of patients with relapsed or refractory multiple myeloma. Longer-term follow-up results from the Phase 1b portion of the study (n=29), to be shared in an oral presentation at the American Society of Clinical Oncology (ASCO) Virtual Scientific Program (Abstract #8505), show that ...
Source: Johnson and Johnson - May 14, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news

ERLEADA ® (apalutamide) Significantly Improved Overall Survival in Patients with Non-Metastatic Castration-Resistant Prostate Cancer
RARITAN, NJ, May 13, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today results from the final analysis of the pivotal Phase 3 SPARTAN study demonstrating ERLEADA® (apalutamide) in combination with androgen deprivation therapy (ADT) significantly improved overall survival (OS), compared to ADT alone, in patients with non-metastatic castration-resistant prostate cancer (nmCRPC) who were at high risk of developing metastases.[i] Results will be presented at the American Society of Clinical Oncology (ASCO) Virtual Scientific Program (Abstract #5516) beginning May 29th. ERLEADA® in combina...
Source: Johnson and Johnson - May 14, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news